Quantcast

Got Stocks from QualityStocks Ones To Watch

Got Stocks

Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...




Untitled Document

Nexeon MedSystems, Inc. (NXNN)

Nexeon MedSystems, Inc. concentrates on providing innovative neurostimulation products. Its focus is on providing neurostimulation products that improve the quality-of-life of patients suffering from debilitating neurological diseases. A global bioelectronics medical device company, Nexeon MedSystems has offices in Dallas, Texas and Liege, Belgium (Nexeon MedSystems Belgium SPRL).

Nexeon has developed and commercialized a neurostimulation system. This system can be used to treat a variety of neurological diseases.

Neurostimulation systems are utilized to restore neuronal function. The company's SYNAPSE™ device is the platform used in a process called Deep Brain Stimulation (DBS).

This platform acts like a brain pacemaker sending electrical pulses to specifically targeted areas in the brain. SYNAPSE™ reduces shortcomings in contemporary DBS therapy. It enables the detection, measurement, as well as collection of brain signals, while simultaneously providing targeted DBS therapy. Furthermore, it provides directional stimulation that limits side effects.

In addition, multiple stimulation frequencies allow increased therapy range. Additionally, rechargeable means a greater range of available therapies and rechargeable enables one surgery in comparison to many. The plan is for the DBS commercial launch in Q2 of 2018.

Nexeon MedSystems earlier exercised its option to acquire Nexeon Medsystems Belgium, SPRL (NMB). NMB has been operating since 2013 developing neurostimulation products.

NMB recently acquired Medi-Line. This is a Belgian medical device manufacturer. Medi-Line currently serves 34 medical device customers in 16 nations. It has multi-year contracts with Fortune 500 companies.

Nexeon MedSystems announced in October of 2017 its completion of an initial series of clinical studies evaluating the use of transcutaneous auricular vagus nerve stimulation (aVNS) for the relief of paroxysmal atrial fibrillation. The company was previously awarded a €3.4M research grant regarding this study from the Walloon Region government of Belgium in coordination with the region's health competitiveness cluster BioWin.

For Q3 2017, Nexeon MedSystems closed the acquisition of Nexeon MedSystems Belgium, SPRL (previously Rosellini Scientific Benelux) and its wholly-owned subsidiaries Med-Line S.A. and its holding company INGEST, SPRL. The company also completed regulatory pathway review with the European regulatory body DEKRA and the Food and Drug Administration (FDA) for its flagship deep brain stimulation product.

 

 

 

The QualityStocks
Newsroom

Read the articles covering the biggest movers in the markets today.

Continue

Market
Basics

Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.

Continue

The QualityStocks Daily
Archives

Go back to see our previous newsletters and find out what you might have missed.

Continue